![David S. Arrington](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Storia della carriera di David S. Arrington
Precedenti posizioni note di David S. Arrington
Società | Posizione | Inizio | Fine |
---|---|---|---|
ACHAOGEN | Contatto Relazioni con gli Investitori | 01/07/2017 | 01/04/2018 |
Public Communications Contact | 01/07/2017 | 01/04/2018 | |
FREELINE THERAPEUTICS HOLDINGS PLC | Contatto Relazioni con gli Investitori | - | - |
Public Communications Contact | - | - | |
COHERUS BIOSCIENCES, INC. | Contatto Relazioni con gli Investitori | 01/09/2018 | - |
Public Communications Contact | 01/09/2018 | - |
Formazione di David S. Arrington
Washington State University | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 4 |
Regno Unito | 2 |
Posizioni
Investor Relations Contact | 3 |
Public Communications Contact | 3 |
Undergraduate Degree | 1 |
Settori
Health Technology | 4 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
COHERUS BIOSCIENCES, INC. | Health Technology |
Aziende private | 2 |
---|---|
Achaogen, Inc.
![]() Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Freeline Therapeutics Holdings Plc
![]() Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- David S. Arrington
- Esperienza